Invitae Corp
DelistedCIK 1501134fmd_1K97NGWNWDED483MM42SD81YQ9Services · Services-Medical LaboratoriesTemplate: Standard
Coverage: Jan 01, 2013 to Sep 30, 2023, 40 periods
| Line item | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 2 | 8 | 25 | 68 | 148 | 217 | 280 | 460 | 516 |
| Cost of revenue | 1 | 6 | 17 | 28 | 50 | 80 | 118 | 198 | 349 | 417 |
| Gross profit | (1) | (4) | (8) | (3) | 18 | 68 | 99 | 81 | 112 | 99 |
| Research and development | 16 | 22 | 43 | 45 | 46 | 63 | 142 | 241 | 416 | 402 |
| Selling, general and administrative | 8 | 21 | 39 | 53 | 93 | 127 | 201 | 438 | 474 | 411 |
| Operating income | (25) | (47) | (89) | (100) | (121) | (123) | (244) | (652) | (392) | (3,118) |
| Interest expense | 0 | 0 | 0 | 0 | 4 | 7 | 12 | 30 | 50 | 57 |
| Interest and investment income | – | – | – | – | – | 2 | 5 | 4 | 7 | 7 |
| Other non-operating income (expense) | (0) | (0) | (0) | 0 | (0) | (3) | (4) | (32) | 26 | 24 |
| Income before taxes | (25) | (47) | (90) | (100) | (125) | (132) | (260) | (714) | (416) | (3,151) |
| Income tax expense | – | 0 | 0 | 0 | (2) | (3) | (18) | (112) | (37) | (45) |
| Net income from continuing operations | – | (47) | (90) | (100) | (123) | (129) | (242) | (602) | (379) | (3,106) |
| Net income | (25) | (47) | (90) | (100) | (123) | (129) | (242) | (602) | (379) | (3,100) |
| Net income to common shareholders | (25) | (47) | (90) | – | – | – | – | – | – | – |